Lisa M. Landrum

Oncology
11700 N Meridian St
Carmel, IN 46032

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications

Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.

Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.

Journal: Gynecologic oncology
Published: March 24, 2026

Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 13, 2026

Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: February 11, 2026

Intrinsic tumor factors and extrinsic environmental and social exposures contribute to endometrial cancer recurrence patterns.

Intrinsic tumor factors and extrinsic environmental and social exposures contribute to endometrial cancer recurrence patterns.

Journal: Research square
Published: February 06, 2026

Real-world monitoring and clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE study.

Real-world monitoring and clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE study.

Journal: Gynecologic oncology
Published: December 17, 2025

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: August 05, 2025

Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.

Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.

Journal: Gynecologic oncology
Published: July 11, 2025

Training, Validating, and Testing Machine Learning Prediction Models for Endometrial Cancer Recurrence.

Training, Validating, and Testing Machine Learning Prediction Models for Endometrial Cancer Recurrence.

Journal: JCO precision oncology
Published: May 05, 2025

A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel.

A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel.

Journal: Therapeutic advances in medical oncology
Published: December 20, 2024

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.

Journal: Nature medicine
Published: September 23, 2024

MYC and HSF1 Cooperate to Drive Sensitivity to Polo-like Kinase 1 Inhibitor Volasertib in High-grade Serous Ovarian Cancer.

MYC and HSF1 Cooperate to Drive Sensitivity to Polo-like Kinase 1 Inhibitor Volasertib in High-grade Serous Ovarian Cancer.

Journal: Cancer research communications
Published: August 09, 2024

A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".

A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".

Journal: Future oncology (London, England)
Published: July 11, 2024
Showing 1-12 of 63

Last Updated: 09/26/2026